Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 1Kidney Neoplasms 1Endometrial Neoplasms 1Cystadenocarcinoma, Serous 1Carcinoma, Renal Cell 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 21Radiotherapy 9Chemotherapy, Adjuvant 9Early Intervention, Educational 8Specimen Handling 7Anastrozole 7Neoadjuvant Therapy 6Methods 6Letrozole 6Practice Guidelines as Topic 5Counseling 5Biopsy 5Standard of Care 4Magnetic Resonance Spectroscopy 4Educational Status 4Behavior Therapy 4exemestane 3Radiation Dose Hypofractionation 3Radiation 3Psychiatric Rehabilitation 3Mastectomy, Segmental 3Brachytherapy 3Therapeutics 2Telemedicine 2Taxes 2Surveys and Questionnaires 2Soybean Proteins 2Simvastatin 2Radiotherapy, Conformal 2Proton Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Carcinoma In Situ × Cimetidine × Clear all
NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Ohio State University Comprehensive Cancer Center

Phase 2/3 Completed
130 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡